Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|September 6, 2012
Industry Briefs: September 3, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Advertisement
Company News
Aesica has announced a partnership with the Center for Pharmaceutical Engineering Science at the University of Bradford in the United Kingdom. The agreement will enable Bradford scientists to use the GMP capabilities and assets held at Aesica while Aesica will have access to the center’s research facilities.
Astellas Pharma and Medivation have received FDA approval for Xtandi (enzalutamide) capsules, a new molecular entity for treating metastatic castration-resistant prostate cancer.
Charles River Laboratories has acquired Accugenix, a provider of cGMP-compliant contract microbial-identification testing, for approximately $17 million in cash.
Cobra Biologics and Algeta have entered into a contract manufacturing partnership for Algeta’s fourth targeted thorium conjugate program. The program will focus on the development of an undisclosed monoclonal antibody, which is highly selective for a validated cell surface target on hematological cancer cells, linked to Algeta’s alpha-particle emitter thorium-227.
Cellceutix has selected Dr. Reddy’s Laboratories for the manufacturing of Prurisol, the company’s new drug candidate for treating psoriasis.
Marken has opened new pharmaceutical depots in Frankfurt, Germany and in Farmingdale, New York.
Mylan’s India-based subsidiary Mylan Laboratories has been selected as a supplier of antiretroviral drugs to India’s National AIDS Control Organization.
VLST, a biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, has announced an in-licensing agreement with Pfizer for an anti-CD40 monoclonal antibody.
West, a manufacturer of components and systems for injectable drug delivery, has announced an agreement with Janssen Biotech to collaborate on the development and manufacturing of a self-injection product.
WuXi PharmaTech a pharmaceutical, biotechnology, and medical-device R&D outsourcing company, and Open Monoclonal Technology (OMT), a company that specializes in transgenic animals for development of human therapeutic antibodies, have entered into an agreement to use OMT’s OmniRat to develop therapeutic antibody candidates for commercialization by WuXi’s global customers.
People Notes
CMC Biologics has appointed Patricio E. Massera as general manager of the company’s Copenhagen facility.
Hovione has named Mike Ironside general manager of the company’s Technology Transfer Center.
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement